As with most you I’m sure – this week the PharmaTell Team had Eyes On ASCO. Plus we saw some positive data for women suffering Postpartum Depression that we thought we would share.
Biogen / Sage Therapeutics
Phase 3 Data from the SKYLARK trial showed that women taking zuranolone for postpartum depression showed clinically meaningful improvement in depressive symptoms at Day 15 compared to placebo. A major step forward for treatments for this patient population. See more details Medicaldialogues, Studio, & Studio.
Reviews from the congress are varied depending on which company / class you follow. We saw outstanding -perhaps even SOC altering – data readouts mixed with trial disappointments.
Astra Zeneca / Daiichi Positive DESTINY-Breast04 Data
Enhertu data presented at ASCO and published in NEJM could open up treatment options for patients who are currently categorized as HER2-negative. The Phase 3 Data from DESTINY-Breast04 trial showed the treatment reduced risk of disease progression or death by 50%, and risk of death in previously treated HER2-low patients by 36%. More details can be found FiercePharma & Studio.
Pfizer Ibrance + Letrozole Did Not Improve OSR
Phase 3 trial of Ibrance + Letrozole in ER+, HER2-metastatic breast cancer did not improve overall survival rate in patients. Though the Ph 2 data on which it was approved showed improved progression free survival (24.8 mo vs 12.5 mo) vs Letrozole alone, as well as delaying time to chemotherapy, the OSR in the Ph 3 trial was not statistically different. These data are the latest in a series of Ibrance trial results showing mixed results in disease free survival (versus previous data showing improvements in progression-free and overall survival). Pfizer states that there are compelling benefits from the Ph 3 trial showing delayed time to Chemo, maintenance of QoL and a consistent safety profile and they are still confident in its ability to help improve the lives of patients. More details Biospace & Studio.
Some of the latest ASCO summary reports in Studio can be found here: Studio, Studio, & Studio.
Amgen Vectibix in colon cancer
We also saw a Reuters article about the Amgen Vectibix trial results. Results show that Vectibix – a monoclonal antibody, an EGFR inhibitor -extends survival in specific inoperable colon cancers. The risk of death during the 5-year study was 18% lower for patients with left-side tumors that were taking Vectibix in combination with standard chemo rather than Avastin. In addition, some patients had tumor reduction to the extent that surgery became an option.
Tip of the Week
There are many new reports in PharmaTell Studio related to ASCO, including data reviews, KOL thoughts, and company discussions. You can search multiple ways:
- In the keyword search type in “ASCO” and limit the start date to June 1 2022
- In the company catalogue enter “ASCO” in the search box and limit the start date to June 1 2022.
- In the Therapeutic catalogue enter “ASCO” in the search box and limit the start date to June 1 2022.
If you haven’t activated your PharmaTell Studio account and can’t access the links or if you are interested in a free trial of PharmaTell, please send us an email to email@example.com and we will be happy to assist you.
What were you keeping your eyes on this week? Feel free to comment or drop us a note on the Pharma Intel you are tracking. ‘Til next time – Robin